
KFF Analysis Finds Mixed Results for TrumpRx Drug Prices vs. Global Peers
A new analysis by the Kaiser Family Foundation (KFF) reveals that the TrumpRx website delivers mixed results for Americans seeking lower prescription drug prices. While prices for 17 brand-name drugs are lower than the average in 11 peer nations, 15 drugs cost significantly more. The site, which targets cash-paying consumers, does not guarantee the 'lowest prices in the developed world' as claimed by the administration. Notable exceptions include weight-loss drugs like Ozempic and Zepbound, which remain more expensive in the U.S. than in comparable countries. This finding contrasts with the administration's broader 'most favored nation' strategy, which has secured deals with 26 pharmaceutical companies and enrolled all 50 states in Medicaid pricing reforms.

